CN107751796A - 一种哺乳期营养粉及其制备方法 - Google Patents
一种哺乳期营养粉及其制备方法 Download PDFInfo
- Publication number
- CN107751796A CN107751796A CN201710786190.8A CN201710786190A CN107751796A CN 107751796 A CN107751796 A CN 107751796A CN 201710786190 A CN201710786190 A CN 201710786190A CN 107751796 A CN107751796 A CN 107751796A
- Authority
- CN
- China
- Prior art keywords
- powder
- wheat germ
- nursing period
- raw material
- period nutrient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000843 powder Substances 0.000 title claims abstract description 108
- 230000000474 nursing effect Effects 0.000 title claims abstract description 39
- 235000015097 nutrients Nutrition 0.000 title claims abstract description 37
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- 241000209140 Triticum Species 0.000 claims abstract description 70
- 235000021307 Triticum Nutrition 0.000 claims abstract description 70
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims abstract description 42
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 42
- 239000002994 raw material Substances 0.000 claims abstract description 32
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940114079 arachidonic acid Drugs 0.000 claims abstract description 21
- 235000021342 arachidonic acid Nutrition 0.000 claims abstract description 21
- 229960000304 folic acid Drugs 0.000 claims abstract description 21
- 235000019152 folic acid Nutrition 0.000 claims abstract description 21
- 239000011724 folic acid Substances 0.000 claims abstract description 21
- 229920001202 Inulin Polymers 0.000 claims abstract description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 235000019197 fats Nutrition 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 239000011574 phosphorus Substances 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 abstract description 9
- 230000006651 lactation Effects 0.000 abstract description 8
- 210000001161 mammalian embryo Anatomy 0.000 abstract description 7
- 230000009469 supplementation Effects 0.000 abstract description 5
- 239000011573 trace mineral Substances 0.000 abstract description 5
- 235000013619 trace mineral Nutrition 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 24
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 22
- 230000000694 effects Effects 0.000 description 7
- 230000035764 nutrition Effects 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000004641 brain development Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 206010000234 Abortion spontaneous Diseases 0.000 description 2
- 235000007516 Chrysanthemum Nutrition 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940090949 docosahexaenoic acid Drugs 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000723353 Chrysanthemum Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 244000298479 Cichorium intybus Species 0.000 description 1
- 235000007542 Cichorium intybus Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016880 Folate deficiency Diseases 0.000 description 1
- 208000010188 Folic Acid Deficiency Diseases 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 1
- 206010036600 Premature labour Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000000431 corpus luteum hormone Substances 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000000412 dendrimer Substances 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007235 immunity generation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- -1 lipositol Chemical compound 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 208000015994 miscarriage Diseases 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000019240 optic nerve development Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000036417 physical growth Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000026440 premature labor Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- CEIZFXOZIQNICU-UHFFFAOYSA-N tenuazonic acid Chemical compound CCC(C)C1NC(=O)C(C(C)=O)=C1O CEIZFXOZIQNICU-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了一种哺乳期营养粉及其制备方法，属于营养粉生产技术领域。所述哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉90.1492‑92.7496％、叶酸0.0004‑0.0008％、DHA粉末2.5‑3.0％、花生四烯酸粉末0.45‑0.50％、磷脂0.30‑0.35％和菊粉4‑6％。本发明还公开了上述哺乳期营养粉的制备方法。本发明以小麦胚芽为原料，可以为哺乳期女性提供哺乳期间所需的营养补充及微量元素，改善母体由于哺乳引起的必须脂肪酸不足的现象。
Description
技术领域
本发明涉及一种哺乳期营养粉及其制备方法，属于营养粉生产技术领域。
背景技术
我国长期倡导“晚婚”、“晚育”的生育政策，现代人婚恋观念也随之改变，“大龄未孕”现象普遍，加之环境污染、工作压力大等原因，使很多适龄及超龄夫妇“想孕而不得”，因此迫切需要一种绿色、有机、无添加，且能辅助适龄及超龄夫妇备孕的健康食品来满足这样的需求。
发明内容
本发明的目的之一，是提供一种哺乳期营养粉。本发明以小麦胚芽为原料，可以为哺乳期女性提供哺乳期间所需的营养补充及微量元素，改善母体由于哺乳引起的必须脂肪酸不足的现象。
本发明解决上述技术问题的技术方案如下：一种哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉90.1492-92.7496％、叶酸0.0004-0.0008％、DHA粉末2.5-3.0％、花生四烯酸粉末0.45-0.50％、磷脂0.30-0.35％和菊粉4-6％。
本发明所采用的原料的作用和功效：
麦胚粉，以新鲜麦胚为原料，经干燥、炒制、粉碎后所得。麦胚，又称小麦胚芽、麦芽粉、胚芽，金黄色颗粒状，是小麦发芽及生长的器官，约占整个麦粒的2.5％，是小麦籽粒的精华，营养成分丰富，含有极其丰富的蛋白质、脂肪、多种维生素、钙、钾、镁、铁、锌、铬、硒、磷、锰、铜等多种矿物质和微量元素，被营养学家们誉为“人类天然的营养宝库”。《本草纲目》记载：“麦胚可治心悸失眠，养心安神，养肝气，止泻，降压，健胃”。美国营养学博士哈桑先生在《想年轻长生不老》写道“小麦胚芽包含着丰富均衡的且对生长发育又是必需的营养素，半杯小麦胚芽胜过四个鸡蛋的蛋白质成份。”小麦胚芽蛋白是一种完全蛋白，含有人体必需的8种氨基酸，占总氨基酸的34.7％。特别是在氨基酸中，蛋氨酸占2％，组氨酸占2.5％，而一般谷物中短缺的，能有效促进幼儿生长和发育的，人类第一限制性氨基酸——赖氨酸的含量高达18.5g/kg，远远高出大米、面粉。麦胚能提高黄体荷尔蒙及女性荷尔蒙分泌的作用，以提高生殖力，治疗不孕症及消除早产，流产等危险现象，保护母体的安全。
叶酸，为市面购买。叶酸是一种含单一有效成分的维生素，能够预防胎宝宝畸形，从孕前3个月开始，直到孕后3个月结束，每天需要补充0.4-1mg叶酸。叶酸缺乏可导致胎儿畸形，包括无脑儿、脊柱裂等，还可引起早期的自然流产。
DHA粉末，为市面购买。DHA，中文名：二十二碳六烯酸，英语：DocosahexaenoicAcid，是有六个双键的多元不饱和脂肪酸(C22H32O2)，是一种ω-3必需脂肪酸。DHA，可以促进胎儿大脑发育、促进视网膜光感细胞的成熟。在孕期，DHA能优化胎儿大脑锥体细胞的磷脂的构成成分。尤其胎儿满5个月后，如人为地对胎儿的听觉、视觉、触觉进行刺激，会引起胎儿大脑皮层感觉中枢的神经元增长更多的树突，这就需要母体同时供给胎儿更多的DHA。DHA不仅对胎儿大脑发育有重要影响，而且对视网膜光感细胞的成熟有重要作用。孕妇在孕期可通过摄入DHA，然后输送到胎儿大脑和视网膜，使神经细胞成熟度提高。
花生四烯酸粉末，为市面购买。花生四烯酸，含有四个碳-碳双键，一个碳-氧双键，为高级不饱和脂肪酸。广泛分布于动物界，少量存在于某个种的甘油酯中，也能在甘油磷脂类中找到。花生四烯酸是人体大脑和视神经发育的重要物质，对提高智力和增强视敏度具有重要作用。
磷脂，为市面购买。磷脂，是含有磷脂根的类脂化合物，是生命基础物质。而细胞膜就由40％左右蛋白质和50％左右的脂质(磷脂为主)构成。它是由卵磷脂，肌醇磷脂，脑磷脂等组成。这些磷脂分别对人体的各部位和各器官起着相应的功能。磷脂对活化细胞，维持新陈代谢，基础代谢及荷尔蒙的均衡分泌，增强人体的免疫力和再生力，都能发挥重大的作用。另外，磷脂还具有促进脂肪代谢，防止脂肪肝，降低血清胆固醇、改善血液循环、预防心血管疾病的作用。
菊粉，以菊苣根为原料，经去除蛋白质和矿物质、喷雾干燥后所得，为市面购买。菊苣根，为菊科植物菊苣的根。气微，味淡，有清肝利胆、健胃消食、利尿消肿之功效，用于湿热黄疸、胃痛食少、水肿尿少等病症。菊粉中含有一种功能性强、水溶性好的植物多糖——低聚果糖，具有以下作用：增殖人体内双歧杆菌，可抑制腐败菌的生长，促进肠道蠕动，调节肠胃功能；促进维生素的合成和矿物质吸收，增强免疫，提高免疫力；排除体内毒素，减轻肝、肾等脏器负担；改善脂质代谢，降低血脂、胆固醇及脂肪；5、控制血糖，防止龋齿等。
在上述技术方案的基础上，本发明还可以做如下改进。
进一步，按原料的总重量的百分含量计，由如下原料制成：麦胚粉91.4328％、叶酸0.0006％、DHA粉末2.75％、花生四烯酸粉末0.4833％、磷脂0.3333％和菊粉5％。
采用上述进一步的有益效果是：此为最佳参数。采用上述参数，得到的哺乳期营养粉的效果最好。
本发明的目的之二，是提供上述哺乳期营养粉的制备方法。本发明的制备方法简单，市场前景广阔，适合规模化生产。
本发明解决上述技术问题的技术方案如下：一种哺乳期营养粉的制备方法，包括如下步骤：
步骤1：制备麦胚粉
步骤1.1干燥：取新鲜麦胚，于55-65℃，干燥10-20分钟，得到干燥后的麦胚；
步骤1.2炒制：将步骤1.1得到的干燥后的麦胚，炒制30-40分钟，得到炒制后的麦胚；
步骤1.3粉碎：将步骤1.2得到的炒制后的麦胚，粉碎，过筛，得到麦胚粉；
步骤2：混合
一种哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉97.3492-97.8996％、叶酸0.0004-0.0008％、DHA粉末1.5-1.8％、花生四烯酸粉末0.30-0.45％和磷脂0.30-0.40％，取步骤1得到的麦胚粉，再取叶酸、DHA粉末、花生四烯酸粉末、磷脂和菊粉，分别粉碎，过筛，混合均匀，即得到所述哺乳期营养粉。
在上述技术方案的基础上，本发明还可以做如下改进。
进一步，步骤1.2所述炒制后的麦胚的含水率≤3wt％。
进一步，步骤1.3所述过筛的目数为80目。
进一步，步骤2所述过筛的目数为80目。
本发明的营养粉的规格为20g/袋，3袋/日，即按照每日服用60g计算。
本发明的有益效果是：
(1)本发明以小麦胚芽为原料，可以为哺乳期女性提供哺乳期间所需的营养补充及微量元素，改善母体由于哺乳引起的必须脂肪酸不足的现象。
(2)本发明的制备方法简单，市场前景广阔，适合工业化生产。
具体实施方式
以下结合具体实施例对本发明的原理和特征进行描述，所举实例只用于解释本发明，并非用于限定本发明的范围。
实施例1：
本实施例的哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉90.1492％、叶酸0.0008％、DHA粉末3.0％、花生四烯酸粉末0.50％、磷脂0.35％和菊粉6％。
本实施例的哺乳期营养粉的制备方法，包括如下步骤：
步骤1：制备麦胚粉
步骤1.1干燥：取新鲜麦胚，于55℃，干燥20分钟，得到干燥后的麦胚；
步骤1.2炒制：将步骤1.1得到的干燥后的麦胚，炒制30分钟，得到含水率为3wt％的炒制后的麦胚；
步骤1.3粉碎：将步骤1.2得到的炒制后的麦胚，粉碎，过80目筛，得到麦胚粉；
步骤2：混合
一种哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉90.1492％、叶酸0.0008％、DHA粉末3.0％、花生四烯酸粉末0.50％、磷脂0.35％和菊粉6％，取步骤1得到的麦胚粉，再取叶酸、DHA粉末、花生四烯酸粉末、磷脂和菊粉，分别粉碎，过80目筛，混合均匀，即得到所述哺乳期营养粉。
实施例2：
本实施例的哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉91.4328％、叶酸0.0006％、DHA粉末2.75％、花生四烯酸粉末0.4833％、磷脂0.3333％和菊粉5％。
本实施例的哺乳期营养粉的制备方法，包括如下步骤：
步骤1：制备麦胚粉
步骤1.1干燥：取新鲜麦胚，于60℃，干燥15分钟，得到干燥后的麦胚；
步骤1.2炒制：将步骤1.1得到的干燥后的麦胚，炒制35分钟，得到含水率为2.5wt％的炒制后的麦胚；
步骤1.3粉碎：将步骤1.2得到的炒制后的麦胚，粉碎，过80目筛，得到麦胚粉；
步骤2：混合
一种哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉91.4328％、叶酸0.0006％、DHA粉末2.75％、花生四烯酸粉末0.4833％、磷脂0.3333％和菊粉5％，取步骤1得到的麦胚粉，再取叶酸、DHA粉末、花生四烯酸粉末、磷脂和菊粉，分别粉碎，过80目筛，混合均匀，即得到所述哺乳期营养粉。
实施例3：
本实施例的哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉92.7496％、叶酸0.0004％、DHA粉末2.5％、花生四烯酸粉末0.45％、磷脂0.30％和菊粉4％。
本实施例的哺乳期营养粉的制备方法，包括如下步骤：
步骤1：制备麦胚粉
步骤1.1干燥：取新鲜麦胚，于65℃，干燥10分钟，得到干燥后的麦胚；
步骤1.2炒制：将步骤1.1得到的干燥后的麦胚，炒制40分钟，得到含水率为2wt％的炒制后的麦胚；
步骤1.3粉碎：将步骤1.2得到的炒制后的麦胚，粉碎，过80目筛，得到麦胚粉；
步骤2：混合
一种哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉92.7496％、叶酸0.0004％、DHA粉末2.5％、花生四烯酸粉末0.45％、磷脂0.30％和菊粉4％，取步骤1得到的麦胚粉，再取叶酸、DHA粉末、花生四烯酸粉末、磷脂和菊粉，分别粉碎，过80目筛，混合均匀，即得到所述哺乳期营养粉。
实施例1-3所得哺乳期营养粉的检测指标，具体如表1所示。
表1实施例1-3所得哺乳期营养粉的检测指标
由此可见，本发明可以为哺乳期女性提供哺乳期间所需的营养补充及微量元素，改善母体由于哺乳引起的必须脂肪酸不足的现象。
以上所述仅为本发明的较佳实施例，并不用以限制本发明，凡在本发明的精神和原则之内，所作的任何修改、等同替换、改进等，均应包含在本发明的保护范围之内。
Claims (6)
1.一种哺乳期营养粉，其特征在于，按原料的总重量的百分含量计，由如下原料制成：麦胚粉90.1492-92.7496％、叶酸0.0004-0.0008％、DHA粉末2.5-3.0％、花生四烯酸粉末0.45-0.50％、磷脂0.30-0.35％和菊粉4-6％。
2.根据权利要求1所述的一种哺乳期营养粉，其特征在于，按原料的总重量的百分含量计，由如下原料制成：麦胚粉91.4328％、叶酸0.0006％、DHA粉末2.75％、花生四烯酸粉末0.4833％、磷脂0.3333％和菊粉5％。
3.一种哺乳期营养粉的制备方法，其特征在于，包括如下步骤：
步骤1：制备麦胚粉
步骤1.1干燥：取新鲜麦胚，于55-65℃，干燥10-20分钟，得到干燥后的麦胚；
步骤1.2炒制：将步骤1.1得到的干燥后的麦胚，炒制30-40分钟，得到炒制后的麦胚；
步骤1.3粉碎：将步骤1.2得到的炒制后的麦胚，粉碎，过筛，得到麦胚粉；
步骤2：混合
一种哺乳期营养粉，按原料的总重量的百分含量计，由如下原料制成：麦胚粉97.3492-97.8996％、叶酸0.0004-0.0008％、DHA粉末1.5-1.8％、花生四烯酸粉末0.30-0.45％和磷脂0.30-0.40％，取步骤1得到的麦胚粉，再取叶酸、DHA粉末、花生四烯酸粉末、磷脂和菊粉，分别粉碎，过筛，混合均匀，即得到所述哺乳期营养粉。
4.根据权利要求3所述的一种哺乳期营养粉的制备方法，其特征在于，步骤1.2所述炒制后的麦胚的含水率≤3wt％。
5.根据权利要求3所述的一种哺乳期营养粉的制备方法，其特征在于，步骤1.3所述过筛的目数为80目。
6.根据权利要求3所述的一种哺乳期营养粉的制备方法，其特征在于，步骤2所述过筛的目数为80目。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710786190.8A CN107751796A (zh) | 2017-09-04 | 2017-09-04 | 一种哺乳期营养粉及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710786190.8A CN107751796A (zh) | 2017-09-04 | 2017-09-04 | 一种哺乳期营养粉及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107751796A true CN107751796A (zh) | 2018-03-06 |
Family
ID=61265910
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710786190.8A Pending CN107751796A (zh) | 2017-09-04 | 2017-09-04 | 一种哺乳期营养粉及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107751796A (zh) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090006892A (ko) * | 2007-07-02 | 2009-01-16 | 주식회사 유맥스 | 초임계 유체 처리 후 도정한 곡물을 이용한 임산부용 밥 |
| CN101664127A (zh) * | 2009-09-05 | 2010-03-10 | 泰祥集团技术开发有限公司 | 一种营养粉及其制备方法 |
| CN102379345A (zh) * | 2011-09-29 | 2012-03-21 | 黑龙江飞鹤乳业有限公司 | 一种适合孕产妇饮用的调制乳及其生产工艺 |
| CN102488011A (zh) * | 2011-12-21 | 2012-06-13 | 澳优乳业（中国）有限公司 | 一种含花生四烯酸的孕产妇配方奶粉及其制备方法 |
| CN105707707A (zh) * | 2016-03-28 | 2016-06-29 | 苟春虎 | 藜麦孕产妇超级营养粉 |
-
2017
- 2017-09-04 CN CN201710786190.8A patent/CN107751796A/zh active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20090006892A (ko) * | 2007-07-02 | 2009-01-16 | 주식회사 유맥스 | 초임계 유체 처리 후 도정한 곡물을 이용한 임산부용 밥 |
| CN101664127A (zh) * | 2009-09-05 | 2010-03-10 | 泰祥集团技术开发有限公司 | 一种营养粉及其制备方法 |
| CN102379345A (zh) * | 2011-09-29 | 2012-03-21 | 黑龙江飞鹤乳业有限公司 | 一种适合孕产妇饮用的调制乳及其生产工艺 |
| CN102488011A (zh) * | 2011-12-21 | 2012-06-13 | 澳优乳业（中国）有限公司 | 一种含花生四烯酸的孕产妇配方奶粉及其制备方法 |
| CN105707707A (zh) * | 2016-03-28 | 2016-06-29 | 苟春虎 | 藜麦孕产妇超级营养粉 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103005281B (zh) | 高营养保健米及其制备方法 | |
| CN102742837B (zh) | 一种用于改善营养不良症状的保健食品及其制备方法 | |
| CN105380271B (zh) | 无添加剂全籽粒绿豆复合营养粉及其生产方法 | |
| CN103766713A (zh) | 一种玉米复合营养米 | |
| JP2017529086A (ja) | 最適栄養食品 | |
| CN107927754A (zh) | 一种产时供能专用型临床营养配方及其制备方法 | |
| CN104432036A (zh) | 缓解视疲劳的保健营养组合物及其制备方法与应用 | |
| CN101715915A (zh) | 一种全营养复合食用粉 | |
| CN107691794A (zh) | 一种蝴蝶犬幼犬狗粮及其制备方法 | |
| CN104921133A (zh) | 一种女性谷菜果营养食品及其制备方法 | |
| CN102613472A (zh) | 五谷营养馥合粉及其制作方法 | |
| CN106819141A (zh) | 一种含黑芝麻黑豆的千张及其制备方法 | |
| CN105794926A (zh) | 一种辣木低糖营养月饼及其制作方法 | |
| CN107373312A (zh) | 一种调理养生粥粉 | |
| CN107751795A (zh) | 一种备孕期男士营养粉及其制备方法 | |
| CN106509606A (zh) | 一种具有调理孕妇体质的五谷杂粮及其生产工艺 | |
| CN102669575A (zh) | 一种含玉米的保健营养米及其制备方法 | |
| CN108813304A (zh) | 一种紫薯保健米粉 | |
| CN107751796A (zh) | 一种哺乳期营养粉及其制备方法 | |
| CN104116032A (zh) | 一种具有乌发养颜功效的营养早餐及其制备方法 | |
| CN107549634A (zh) | 一种孕期营养粉及其制备方法 | |
| CN102342410A (zh) | 一种黄色杂粮保健产品及其制备方法 | |
| KR20020071152A (ko) | 기능성 식품 조성물 및 그 제조방법 | |
| CN112137099A (zh) | 一种多功能营养食品配方 | |
| CN106666534A (zh) | 一种儿童果蔬超微粉咀嚼片及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180306 |